Company profile
IM Cannabis Corp.
NASDAQ: IMCC · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCCIK 0001792030Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 41DQ —GM —SS 36
v0.1 · 35/100 weight · pillars only
↑ return on assets, workforce scale · ↓ filing timeliness, market scale
Methodology →Revenue TTM
$30.1M
Rev growth YoY (TTM)
-20.0%
Net income (FY)
-$8.4M
Employees
44
as of 2026-08-18
Market cap
$401.1k
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$8.4M-11.8M CAD2025
Total assets$23.2M31.7M CAD2025
Liabilities$25.8M35.4M CAD2025
Revenue by segment
Filed disclosures · FY2025
By product
Cannabis Products100%
By geography
Not disclosed.
The read
What is IM Cannabis Corp.’s financial profile?
IM Cannabis Corp. earned -$8.4M in FY2025 net income.
Peers · Healthcare
PPJ Healthcare Enterprises, Inc.——Mosaic ImmunoEngineering Inc.——Halberd Corporation——Southern Home Medical, Inc.——CBD Life Sciences Inc.——Galexxy Holdings, Inc.——Key facts
CEOOren Shuster
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeNASDAQ: IMCC
Employees44
IPO date2020-05-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.